The role of stromal cancer-associated fibroblasts in pancreatic cancer

D Von Ahrens, TD Bhagat, D Nagrath, A Maitra… - Journal of hematology & …, 2017 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to
conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of …

[HTML][HTML] Extracellular vesicles as an emerging drug delivery system for cancer treatment: Current strategies and recent advances

Z Wang, H Mo, Z He, A Chen, P Cheng - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Cancer is one of the primary causes of death worldwide, and its morbidity and mortality rates
are increasing rapidly. However, standard treatment modalities (surgery, radiotherapy …

Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application

Q Yang, S Li, H Ou, Y Zhang, G Zhu, S Li… - Journal of …, 2024 - Springer
Malignancy is a major public health problem and among the leading lethal diseases
worldwide. Although the current tumor treatment methods have therapeutic effect to a certain …

The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options

B Ferrara, C Pignatelli, M Cossutta, A Citro, J Courty… - Cancers, 2021 - mdpi.com
Simple Summary This review depicts the principal mechanisms involved in the process of
stromal desmoplasia characterizing pancreatic ductal adenocarcinoma (PDAC). The aim of …

Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system

B Crivelli, T Chlapanidas, S Perteghella… - Journal of Controlled …, 2017 - Elsevier
It has been demonstrated that the biological effector of mesenchymal stem/stromal cells
(MSCs) is their secretome, which is composed of a heterogeneous pool of bioactive …

Engineered exosomes for tumor-targeted drug delivery: a focus on genetic and chemical functionalization

A Akbari, F Nazari-Khanamiri, M Ahmadi, M Shoaran… - Pharmaceutics, 2022 - mdpi.com
Cancer is the main cause of death worldwide. The limitations in traditional cancer therapies
provoked the advance and use of several nanotechnologies for more effective and nontoxic …

Mesenchymal stem cells: A living carrier for active tumor-targeted delivery

T Zhang, R Lin, H Wu, X Jiang, J Gao - Advanced Drug Delivery Reviews, 2022 - Elsevier
The strategy of using mesenchymal stem cells (MSCs) as a living carrier for active delivery of
therapeutic agents targeting tumor sites has been attempted in a wide range of studies to …

Recent advances on drug-loaded mesenchymal stem cells with anti-neoplastic agents for targeted treatment of cancer

A Babajani, P Soltani, E Jamshidi, MH Farjoo… - … in bioengineering and …, 2020 - frontiersin.org
Mesenchymal stem cells (MSCs), as an undifferentiated group of adult multipotent cells,
have remarkable antitumor features that bring them up as a novel choice to treat cancers …

The future of mesenchymal stem cell-based therapeutic approaches for cancer–from cells to ghosts

A Mohr, R Zwacka - Cancer letters, 2018 - Elsevier
Mesenchymal stem cells (MSCs) are multipotent stromal cells which can differentiate into a
variety of cell types including osteoblasts, adipocytes and chondrocytes. They are normally …

Mesenchymal stem cells, exosomes and exosome-mimics as smart drug carriers for targeted cancer therapy

H Liu, S Deng, L Han, Y Ren, J Gu, L He, T Liu… - Colloids and Surfaces B …, 2022 - Elsevier
Mesenchymal stem cells (MSCs) are multipotent stem cells with the capacity to differentiate
into several cell types under appropriate conditions. They also possess remarkable …